Hypoxic ischemic encephalopathy (HIE) | Canada Hyperbarics Skip to main content
Review Front Neurol 2024

Hypoxic ischemic encephalopathy (HIE)

Sánchez-Rodríguez E, López V — Front Neurol, 2024

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers reviewed existing medical literature to understand how hyperbaric oxygen therapy (HBOT) is used to treat acute ischemic hypoxic encephalopathy in newborns.

What They Found

The review found that when given early, HBOT can help protect brain tissue that is at risk but not yet fully damaged (the penumbra). It can also reduce inflammation, restore cell function, decrease swelling, improve blood flow, and act as an antioxidant, all of which help save and protect marginal tissue.

What This Means for Canadian Patients

For Canadian newborns suffering from acute ischemic hypoxic encephalopathy, this review suggests that early HBOT could be a valuable additional treatment. It implies that HBOT may help preserve brain tissue, reduce damage, and improve outcomes by addressing inflammation and cellular dysfunction.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

As a review of existing literature, this study summarizes potential mechanisms but does not present new clinical trial data on patient outcomes.

Was this summary helpful?

Study Details

Study Type Review
Category Systematic Reviews
Source Pubmed
PubMed ID 39108657
Year Published 2024
Journal Front Neurol

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.